{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:16:32Z","timestamp":1787015792240,"version":"build-2736575974"},"reference-count":33,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2017,3,30]],"date-time":"2017-03-30T00:00:00Z","timestamp":1490832000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mycoses"],"published-print":{"date-parts":[[2017,8]]},"abstract":"Summary<\/jats:title>\n \n Miconazole is a broad\u2010spectrum antifungal used in topical preparations. In the present investigation the minimal inhibitory concentration (\n MIC<\/jats:styled-content>\n ) of miconazole for eighty wild type strains of gram\u2010positive and gram\u2010negative bacteria isolated from infected skin lesions was assessed using a modified agar dilution test (adapted to\n CLSI<\/jats:styled-content>\n , Clinical Laboratory Standards Institute). 14\n ATCC<\/jats:styled-content>\n reference strains served as controls. Miconazole was found efficacious against gram\u2010positive aerobic bacteria (n=62 species), the\n MIC<\/jats:styled-content>\n s against\n Staphylococcus (S.) aureus<\/jats:italic>\n ,\n S<\/jats:italic>\n . spp.,\n Streptococcus<\/jats:italic>\n spp. und\n Enterococcus<\/jats:italic>\n spp. ranged between 0.78 and 6.25\u00a0\u03bcg\/mL. Interestingly, there were no differences in susceptibility between methicillin\u2010susceptible (\n MSSA<\/jats:styled-content>\n , 3) methicillin\u2010resistant (\n MRSA<\/jats:styled-content>\n , 6) and fusidic acid\u2010resistant\n \n (\n FRSA<\/jats:styled-content>\n ,\n <\/jats:italic>\n 2)\n S.\u00a0aureus<\/jats:italic>\n isolate\n s<\/jats:italic>\n . Strains of\n Streptococcus pyogenes<\/jats:italic>\n (A\u2010streptococci) (8) were found to be slightly more sensitive (0.78\u20101.563\u00a0\u03bcg\/mL), while for gram\u2010negative bacteria, no efficacy was found within the concentrations tested (\n MIC<\/jats:styled-content>\n >200\u00a0\u03bcg\/mL). In conclusion, for the gram\u2010positive aerobic bacteria the\n MIC<\/jats:styled-content>\n s of miconazole were found within a range which is much lower than the concentration of miconazole used in topical preparations (2%). Thus topically applied miconazole might be a therapeutic option in skin infections especially caused by gram\u2010positive bacteria even by those strains which are resistant to antibiotics.\n <\/jats:p>","DOI":"10.1111\/myc.12620","type":"journal-article","created":{"date-parts":[[2017,3,30]],"date-time":"2017-03-30T05:48:58Z","timestamp":1490852938000},"page":"552-557","source":"Crossref","is-referenced-by-count":53,"title":["New insights on the antibacterial efficacy of miconazole in vitro"],"prefix":"10.1111","volume":"60","author":[{"given":"P.","family":"Nenoff","sequence":"first","affiliation":[{"name":"Labor f\u00fcr Medizinische Mikrobiologie R\u00f6tha\/OT M\u00f6lbis Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Koch","sequence":"additional","affiliation":[{"name":"Labor f\u00fcr Medizinische Mikrobiologie R\u00f6tha\/OT M\u00f6lbis Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Kr\u00fcger","sequence":"additional","affiliation":[{"name":"Labor f\u00fcr Medizinische Mikrobiologie R\u00f6tha\/OT M\u00f6lbis Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Drechsel","sequence":"additional","affiliation":[{"name":"Almirall Hermal GmbH Reinbek Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9850-1062","authenticated-orcid":false,"given":"P.","family":"Mayser","sequence":"additional","affiliation":[{"name":"Biebertal Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,3,30]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s001050050754"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00105-016-3851-x"},{"key":"e_1_2_5_4_1","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1111\/ddg.12111","article-title":"Current resistance patterns of Staphylococcus aureus towards topical antibiotics and relevant antiseptics in patients with atopic dermatitis and impetigo","volume":"11","author":"Thum D","year":"2013","journal-title":"J Dtsch Dermatol Ges"},{"key":"e_1_2_5_5_1","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/ddg.12871","article-title":"S2k guideline on diagnosis and treatment of atopic dermatitis\u2013short version","volume":"14","author":"Werfel T","year":"2016","journal-title":"J Dtsch Dermatol Ges"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-0840"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2015.11.017"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2012.687047"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1159\/000220875"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-197509060-00002"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4362.1988.tb01273.x"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.1248\/bpb.33.125"},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-3164.2012.01068.x"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-3164.2012.01040.x"},{"key":"e_1_2_5_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11259-008-9194-z"},{"key":"e_1_2_5_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/vde.12037"},{"key":"e_1_2_5_17_1","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1093\/jac\/dkv056","article-title":"Susceptibility in vitro of canine methicillin\u2010resistant and \u2013susceptible staphylococcal isolates to fusidic acid, chlorhexidine and miconazole: opportunities for topical therapy of canine superficial pyoderma","volume":"70","author":"Clark SM","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"e_1_2_5_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/vde.12357"},{"key":"e_1_2_5_19_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0032-1306765"},{"key":"e_1_2_5_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2012.03880.x"},{"key":"e_1_2_5_21_1","doi-asserted-by":"crossref","unstructured":"ArendrupMC Cuenca\u2010EstrellaM Lass\u2010Fl\u00f6rlC HopeW the Subcommittee on Antifungal Susceptibility Testing (AFST) of the ESCMID European Committee for Antimicrobial Susceptibility Testing (EUCAST).EUCAST Definitive Document EDef 7.2 Revision 2012. Method for the determination of broth dilution minimum Inhibitory concentrations of antifungal agents for yeasts.http:\/\/www.eucast.org\/ast_of_fungi\/publications_in_journals\/(Accessed on 06 May 2016).","DOI":"10.1111\/j.1469-0691.2012.03880.x"},{"key":"e_1_2_5_22_1","unstructured":"Clinical Laboratory Standards Institute.Performance standards for antimicrobial susceptibility testing: twenty\u2010second Informational Supplement. 2012. M100\u2013S22. CLSI Wayne PA."},{"key":"e_1_2_5_23_1","unstructured":"Clinical and Laboratory Standards Institute.Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. 2009. Approved guideline M7\u2010A8. CLSI Wayne PA."},{"key":"e_1_2_5_24_1","unstructured":"Clinical and Laboratory Standards Institute.Performance standards for antimicrobial susceptibility testing. 2009. M100\u2010S19 CLSI Wayne PA."},{"key":"e_1_2_5_25_1","unstructured":"Clinical and Laboratory Standards Institute.Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. 2015. Approved standard: Tenth edition. M07\u2010A10. CLSI Wayne PA."},{"key":"e_1_2_5_26_1","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.12.4.501"},{"key":"e_1_2_5_27_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.5.1837-1843.2005"},{"key":"e_1_2_5_28_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2180-14-65"},{"key":"e_1_2_5_29_1","doi-asserted-by":"publisher","DOI":"10.1080\/0036554021000026926"},{"key":"e_1_2_5_30_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkf217"},{"key":"e_1_2_5_31_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkn456"},{"key":"e_1_2_5_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0625.2008.00734.x"},{"key":"e_1_2_5_33_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00105-009-1751-z"},{"key":"e_1_2_5_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2008.01728.x"}],"container-title":["Mycoses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fmyc.12620","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/myc.12620","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T15:07:53Z","timestamp":1696259273000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/myc.12620"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,30]]},"references-count":33,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["10.1111\/myc.12620"],"URL":"https:\/\/doi.org\/10.1111\/myc.12620","archive":["Portico"],"relation":{},"ISSN":["0933-7407","1439-0507"],"issn-type":[{"value":"0933-7407","type":"print"},{"value":"1439-0507","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,30]]}}}